PhD MD TRR219-associated students
University Hospital RWTH Aachen
Department of Cardiology, Medical Clinic I
Project: The SGLT2 inhibitor ertugliflozin reduces cardiac fibrosis and modulates cardiac substrate metabolism in a mouse model of cardiac hypertrophy
PI: Michael Lehrke
SGLT2 inhibitors reduced heart failure hospitalization in patients with and without diabetes. SGLT2 inhibitors prevent the reabsorption of primarily filtered glucose in the proximal renal tubulus leading to increased urinary glucose excretion and osmotic diuresis. The aim of the project is the investigation of the underlying cardioprotective effects.